TY - JOUR
T1 - P-240 - Beneficial impact of a manganese(III) porphyrin in cancer cell migration
AU - Saraiva, Nuno
AU - Flóridol, Ana
AU - Costa, João
AU - Parsons, Maddy
AU - Batinic-Haberle, Ines
AU - Miranda, Joana Paiva
AU - Castro, Matilde
AU - Oliveira, Nuno Guerreiro
AU - Fernandes, Ana Sofia
PY - 2018/5/20
Y1 - 2018/5/20
N2 - Manganese(III) porphyrins (MnPs) mimic superoxide dismutase, scavenge different reactive species (RS) and modulate redox signaling. MnPs are currently in clinical trials in patients submitted to chemo- or radiotherapy, due to their ability to boost anticancer treatments while protecting off-target tissues. Although RS are implicated in the metastatic process, only scarce studies have addressed the impact of MnPs in metastases. Herein we characterized the impact of non-cytotoxic levels of an MnP (MnTnHex-2-PyP5+) in metastases-related processes. In renal cancer cells 786-O, MnP (0.25 µM) decreased chemotaxis. This MnP (5 μM) was also studied in MCF7 and MDA-MB-231 breast cancer cells alone and in combination with doxorubicin (dox; 0.1 μM). The co-treatment decreased the collective motility of MCF7, the chemotactic migration of both cell lines, and the proteolytic invasion of MDA-MB-231 cells. MnP also counteracted the increase in random MDA-MB-231 cell migration induced by dox. To explore the underlying mechanisms, the effects in cell spread/area, focal adhesions, intracellular RS levels, and NFkB activity were studied. Our results suggest that MnP may have a beneficial impact in reducing cancer cells migration and warrant further studies regarding MnP-based anticancer approaches.
AB - Manganese(III) porphyrins (MnPs) mimic superoxide dismutase, scavenge different reactive species (RS) and modulate redox signaling. MnPs are currently in clinical trials in patients submitted to chemo- or radiotherapy, due to their ability to boost anticancer treatments while protecting off-target tissues. Although RS are implicated in the metastatic process, only scarce studies have addressed the impact of MnPs in metastases. Herein we characterized the impact of non-cytotoxic levels of an MnP (MnTnHex-2-PyP5+) in metastases-related processes. In renal cancer cells 786-O, MnP (0.25 µM) decreased chemotaxis. This MnP (5 μM) was also studied in MCF7 and MDA-MB-231 breast cancer cells alone and in combination with doxorubicin (dox; 0.1 μM). The co-treatment decreased the collective motility of MCF7, the chemotactic migration of both cell lines, and the proteolytic invasion of MDA-MB-231 cells. MnP also counteracted the increase in random MDA-MB-231 cell migration induced by dox. To explore the underlying mechanisms, the effects in cell spread/area, focal adhesions, intracellular RS levels, and NFkB activity were studied. Our results suggest that MnP may have a beneficial impact in reducing cancer cells migration and warrant further studies regarding MnP-based anticancer approaches.
U2 - 10.1016/j.freeradbiomed.2018.04.387
DO - 10.1016/j.freeradbiomed.2018.04.387
M3 - Meeting abstract
SN - 0891-5849
VL - 120, Supplement 1
SP - S117-S118
JO - Free Radical Biology and Medicine
JF - Free Radical Biology and Medicine
ER -
